Acelyrin says goodbye to the drug that got it a $540M IPO in 2023
Acelyrin is officially ending development of an experimental medicine it referred to as a "diamond in the rough" and that served as the foundation for one of the
View Article#ASH24: Gene editing companies seek safer, less grueling conditioning methods...
SAN DIEGO — New and experimental gene therapies made with blood stem cells rely on the same grueling, decades-old methods for a process called conditioning that’s used for bone marrow transplants. It’s...
View ArticleBenevolentAI restructures; Cimeio, Kyowa ink cell therapy deal
Plus, news about NewAmsterdam, Rocket, ImmunityBio, CG Oncology, Spruce Biosciences, Pharming, Veradermics, Noema Pharma, Ambrosia Biosciences, EsoBiotec, Cellectar Biosciences and Hepion:...
View ArticleRelay Therapeutics plans pivotal trial in second-line breast cancer for 2025
Relay Therapeutics’ stock {$RLAY} rose about 6% on Wednesday morning after it released positive interim data for its PI3Kα inhibitor in breast cancer. In the Phase 1/2 trial, 64 patients with...
View ArticlePost-Hoc: What insurance CEO's killing says about US health anger
Years ago when I was visiting Arizona, Congresswoman Gabby Giffords was shot in the head. Giffords had been greeting constituents at a Tucson shopping mall, and I was riding my bike by the complex as ...
View ArticleCandel soars on prostate cancer data despite unclear prospects
Candel Therapeutics’ viral immunotherapy candidate passed a late-stage test in certain patients with prostate cancer, sending its share price {$CADL} up around 60% even as the same treatment flunked a...
View ArticleNIH halts enrollment in trial for SIGA's mpox antiviral after disappointing data
Another trial for SIGA Technologies' mpox antiviral has failed, and all enrollment has been stopped, the NIH's National Institute of Allergy and Infectious Diseases announced this week. SIGA’s...
View ArticleDrugs are approved and available faster in US than most of EU, data show
New drugs in the US were, on average, approved months before winning approval in the EU, according to new data from The IQVIA Institute for Human Data Science. The difference can be attributed in part ...
View ArticleRFK Jr. lobbied against vaccine EUAs. At HHS, he could undo them
Robert F. Kennedy Jr., President-elect Donald Trump's choice to lead the Department of Health and Human Services, would have the ability to quickly act on his efforts two years ago to halt use of Covid...
View ArticleLilly to study obesity drugs in addiction, and is considering cognitive...
With supply shortages fading and new indications growing, the main question for obesity drugmakers entering the new year is what they'll try and treat next with the drugs. For Eli Lilly, one answer is...
View ArticleLonza looks to depart capsule and health ingredients as it undergoes restructure
Only six months into the role, Lonza’s new CEO Wolfgang Wienand is already looking to make his mark. Lonza said Thursday it is planning to exit the capsules and health ingredients market as the Swiss ...
View ArticleCorcept’s ALS drug fails to improve function in Phase 2 study
It’s been a tough few months for Corcept Therapeutics. In October, the company’s lead pipeline candidate missed the primary endpoint in a Phase 3 Cushing’s syndrome trial. Now, its only neurology asset...
View ArticleHealthcare veteran Glen Tullman thinks AI implementation will define health...
While there’s already plenty of AI in healthcare that focuses on administrative tasks on the back end, it’s time for AI in health consumer-facing products to shine in the year ahead, Glen Tullman told...
View ArticlePleno raises $25M for multiomics testing, names new CEO
Pleno has raised an additional $25 million in private funding to advance its tests that detect biological targets for drug research and diagnostics. The company uses what it calls hypercoding, which...
View ArticleKeros halts parts of Phase 2 PAH trial due to safety, stock tanks 70%
Keros Therapeutics said Thursday morning it has voluntarily halted two of three dosing arms of its experimental drug in a Phase 2 trial due to a safety concern. The Boston-area biotech said there was...
View ArticlePfizer shares positive Phase 3 results in breast cancer subset
Pfizer touts Ibrance’s status as a standard of care in HR-positive, HER2-negative metastatic breast cancer. Now the company wants to expand to double-positive patients. On Thursday, the drugmaker...
View ArticleIsomorphic Labs CEO Demis Hassabis bets on biotech's AI future
LONDON — Demis Hassabis has no interest in a laboratory. The Nobel Prize-winning artificial intelligence pioneer is betting big on AI’s future in drug discovery. But he’s also grown exasperated at...
View ArticleEli Lilly and Ro’s unlikely relationship
Over the summer, we speculated that the cold war between drugmakers Eli Lilly and Novo Nordisk and the many businesses profiting from copycat versions of their obesity medications would come ...
View Article